ZIPRECRUITER, INC.

10b5-1 Plans

During the quarter ended June 30, 2026, no individual serving as a director and/or an officer (as defined in Rule 16a-1(f) of the Exchange Act) of our company adopted orterminated a trading plan for the purchase or sale of our securities as described in Item 408 of Regulation S-K.

Amended and Restated Change in Control and Severance Agreements

On July 30, 2026, we entered into amended and restated change in control and severance agreements with certain of our executive officers, including: Ian Siegel, Chief Executive Officer; David Travers, President and interim Chief Financial Officer; Amy Garefis, Executive Vice President, Chief People Officer; Ryan Sakamoto, Executive Vice President, Chief Legal Officer; and Boris Shimanovsky, Executive Vice President, Chief Technology Officer. Carmen Chan, who will commence serving as our Chief Financial Officer and principal financial officer effective as of August 17, 2026, also signed a change in control and severance agreement on the terms described below in connection with her commencement of employment with the Company.

The change in control and severance agreements provide for the following benefits if the executive is terminated by us without cause (as such term is defined in the change in control and severance agreement) outside of a change in control (as such term is defined in the change in control and severance agreement) in exchange for a customary release of claims: (1) a lump sum severance payment of six months’ base salary, (2) a lump sum payment equal to the executive officer’s then-current target bonus opportunity on a prorated basis, and (3) payment of premiums for continued medical benefits (or equivalent cash payment if applicable law so requires) for a period of twelve months.

If the executive officer’s employment is terminated by us without cause or by the executive for good reason within the three months preceding a change in control or within the 12 months following a change in control, the change in control and severance agreements provide the following benefits in exchange for a customary release of claims: (1) a lump sum severance payment of twelve months’ base salary, (2) a lump sum payment equal to the executive officer’s then-current target bonus opportunity, (3) 100% acceleration of any then-unvested equity awards, other than awards that vest on the satisfaction of performance criteria; provided, however, with respect to any outstanding equity awards that would vest only upon satisfaction of performance criteria, such awards shall accelerate and become vested and exercisable as if such awards had been achieved at the greater of (x) actual achievement (if measurable on the date of termination) or (y) target levels, (4) payment of premiums for continued medical benefits (or equivalent cash payment if applicable law so requires) for a period of twelve months, and (5) any unpaid annual bonus for the calendar year prior to the year in which the executive's termination occurs, to the extent earned and not already paid.

The foregoing description of the amended and restated change in control and severance agreements are qualified in their entirety by reference to the full agreement, a form of which is filed as Exhibit 10.2 and incorporated herein by reference.